When considering de-escalation of disease-modifying therapies (DMTs) for patients with multiple sclerosis (MS), a personalized approach guided by a drug’s mechanism of action is critical, as switching from certain agents appears to carry a…
When considering de-escalation of disease-modifying therapies (DMTs) for patients with multiple sclerosis (MS), a personalized approach guided by a drug’s mechanism of action is critical, as switching from certain agents appears to carry a…